Sequential randomization

Handbook of Statistics in Clinical Oncology: Second Edition

Volumn , Issue , 2005, Pages 589-596

  Pater, Joe ^a   Crowley, John ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123815809     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (13)

1. Green S.G., Factorial designs with time to event endpoints. This volume.
2. Byar D.P. et al., Design considerations for AIDS trials. New Engl J Med 323:1343, 1990.
3. Green S.G., Benedetti J., and Crowley J., Clinical Trials in Oncology, 2nd ed., Chapman & Hall/CRC Press, New York, 2003.
4. Salmon S.E. et al., Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 8:1575, 1990.
5. Wahed A.S. and Tsiatis A.A., Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials. Biometrics 60:124, 2004.
6. Tangen, C., Phase II designs with time to event endpoints. This volume.
7. Durie B.G.M. et al., Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. J Clin Oncol 22:1857, 2004.
8. Cooper M.R. et al. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB study. J Clin Oncol 4:1331, 1986.
9. Girling D. et al., Clinical Trials in Cancer. Chapter 4.6. Oxford University Press, New York, 2003.
10. Salmon S.E. et al., Combination chemotherapy, glucocorticoids, and interferon alpha in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 12:2405, 1994.
11. Shustik C. et al., Melphalan-dexamethasone is not superior to melphalan-prednisone as induction therapy in multiple myeloma. Proc Am Soc Clin Oncol 20:298a, 2001.
12. Habermann T.M. et al., Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age or older with diffuse large B-cell lymphoma. Blood 102:8a, 2003.
13. Shustik C. et al., Dexamethasone maintenance versus observation in patients with previously untreated multipe myeloma: a National Cancer Institute of Canada Clinical Trials Group study: MY.7. Proc Am Soc Clin Oncol 23:558, 2004.